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Objective: The objective of this study was to evaluate the association between measures of body composition and
patterns of urine arsenic metabolites in the 1989–1991 baseline visit of the Strong Heart Study, a cardiovascular
disease cohort of adults recruited from rural communities in Arizona, Oklahoma, North Dakota and South Dakota.
Methods: We evaluated 3,663 Strong Heart Study participants with urine arsenic species above the limit of
detection and no missing data on body mass index, % body fat and fat free mass measured by bioelectrical
impedance, waist circumference and other variables. We summarized urine arsenic species patterns as the relative
contribution of inorganic (iAs), methylarsonate (MMA) and dimethylarsinate (DMA) species to their sum. We
modeled the associations of % arsenic species biomarkers with body mass index, % body fat, fat free mass, and
waist circumference categories in unadjusted regression models and in models including all measures of body
composition. We also considered adjustment for arsenic exposure and demographics.
Results: Increasing body mass index was associated with higher mean % DMA and lower mean % MMA before
and after adjustment for sociodemographic variables, arsenic exposure, and for other measures of body
composition. In unadjusted linear regression models, % DMA was 2.4 (2.1, 2.6) % higher per increase in body mass
index category (< 25, ≥25 & <30, ≥30 & <35, ≥35 kg/m2), and % MMA was 1.6 (1.4, 1.7) % lower. Similar patterns
were observed for % body fat, fat free mass, and waist circumference measures in unadjusted models and in models
adjusted for potential confounders, but the associations were largely attenuated or disappeared when adjusted for
body mass index.
Conclusion: Measures of body size, especially body mass index, are associated with arsenic metabolism biomarkers. The
association may be related to adiposity, fat free mass or body size. Future epidemiologic studies of arsenic should
consider body mass index as a potential modifier for arsenic-related health effects.
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Inorganic arsenic (iAs) is a known human carcinogen [1].
Major sources of exposure to inorganic arsenic for the
general population include contaminated water and food
[2-5]. After exposure, iAs is methylated [6] and then elimi-
nated in urine as iAs (~10-30%), monomethylarsonate
(MMA, ~10-20%) and dimethylarsinate (DMA, ~60-80%)
[7-12]. Variation in the pattern of urine metabolites has
been related to arsenic-associated outcomes including* Correspondence: mgribble@jhsph.edu
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reproduction in any medium, provided the orskin lesions [13-15], cancers [16-22] and cardiovascular
diseases [23,24]. This may be due to urine arsenic species
patterns reflecting differential bioavailability across indi-
viduals [25-27] of arsenic species with distinct toxicities
[28-31]. Genetic variants partly determine the pattern of
urine arsenic metabolites [32]. The main enzyme identi-
fied in arsenic methylation reactions is arsenic (III) meth-
yltransferase [33-35] but other enzymes, cofactors, and
transporters may also contribute [32].
Non-genetic determinants of arsenic metabolism may
include sex, smoking, alcohol intake and nutritional
status including dietary folate and vitamin B [36,37].
Recently, increased body mass index has been related toLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from Northern Mexico, Central Europe, and Bangladesh
[10,38,39], although other studies in Bangladesh have been
inconsistent [13,40]. In a study of 303 adolescents from
Taiwan, adolescents with obesity had higher %MMA and
lower %DMA compared to adolescents without obesity
[41], but the differences were not statistically significant.
Body mass index is an imperfect measure of adiposity, as it
reflects both adipose tissue and fat free mass [42]. Other
measures of adiposity or body composition were not evalu-
ated in these studies. Studying the relationships of arsenic
metabolism with other measures of adiposity and body
composition, such as waist circumference (a measure of
central adiposity), body fat and fat free mass, might help to
distinguish whether associations are with adiposity or with
fat free body mass.
The Strong Heart Study (SHS) is a large rural cohort
study with standardized measures of cardiovascular risk
factors including multiple measures of body size and
body composition (body mass index, percent body fat
and fat free mass measured by bioelectrical impedance,
and waist circumference). Participants also provided a spot
urine sample, allowing for the measurement of arsenic
metabolites. The objective of this study was to evaluate the
cross-sectional association of adiposity with the pattern
of urine arsenic metabolites in SHS participants in
1989–1991.Methods
Study population
The recruitment and examination protocols of the SHS
have been described in detail [43]. Briefly, the tribal rolls
from 13 American Indian tribes and communities were
used to recruit the study population, aiming for 1,500
participants at each study center (Arizona, Oklahoma,
and North/South Dakota). A total of 4,549 adults were
recruited in 1989–1991. All participants provided in-
formed consent, and all study protocols were approved
by institutional and Indian Health Service institutional
review boards as well as by the participating tribes.
Total urine arsenic and arsenic species, including iAs,
MMA and DMA were measured in 3,974 participants with
sufficient urine sample available. For this study, we further
excluded one participant missing iAs measurements and
participants with iAs (n = 210), MMA (n = 29) or DMA
(n = 1) below the limit of detection. We also excluded par-
ticipants missing data on body mass index (n = 16), percent
body fat (n = 53), waist circumference (n = 5), education
(n = 4), drinking status (current/ever/never; n = 9) or total
urine arsenic (n = 1), leaving 3,663 participants for the ana-
lysis. The participants included in the analyses were similar
to the overall study population with respect to sociodemo-
graphic characteristics (Additional file 1: Appendix 1).Measures of body composition
Participants were interviewed and physically examined
by centrally trained staff according to a standardized
protocol [43-45]. Participants were examined in the morn-
ing after a 12-hour overnight fast, which included instruc-
tion not to eat breakfast the morning of the visit to the
exam, and to eat or drink nothing but water after 9:00 the
previous evening [43,45]. Each study center had a desig-
nated anthropometry supervisor. Height was measured
standing in centimeters rounded to the nearest integer, and
weight was measured in kilograms using a scale that was
re-zeroed each day and calibrated against a known 50 lb
weight every month or whenever the scale was moved.
Body mass index was calculated by dividing weight in kilo-
grams by height in meters squared. Waist circumference at
umbilicus was measured supine in centimeters rounded
to the nearest integer. The bioelectric impedance was
measured supine on the right side, unless amputated,
using Impedance Meter Model # B1A101 (RJL Equipment
Company) [45]. For the impedance measurements, partic-
ipants were checked by examiners to confirm they had
not exercised vigorously for the past 12 hours, had not
consumed alcohol in the past 24 hours, and were not
dehydrated [45]. We estimated fat free mass and percent-
age of body fat fat freeby equations based on total body
water validated in American Indian populations [46,47].
Watermales Lð Þ ¼
e 1:1782log height cmð Þ½ −0:5968log resistance Ωð Þ½ þ0:3226log weight kgð Þ½ f g:
Waterfemales Lð Þ ¼
e 1:2004log height cmð Þ½ −0:5529log resistance Ωð Þ½ þ0:2164log weight kgð Þ½ f g:
Fat free mass LBMð Þ in kilograms ¼ water Lð Þ=0:732:
% body fat ¼ weight−LBMð Þ=weight½   100%
Urine arsenic metabolites
Spot urine samples collected at the 1989–91 baseline
visit were stored at -80°C at the Penn Medical Labora-
tory, MedStar Health Research Institute (Hyattsville, MD
and Washington, DC, USA) (Lee et al. 1990). In 2009, ali-
quots of up to 1.0 mL from each participant were shipped
to the Trace Element Laboratory of the Institute of
Chemistry-Analytical Chemistry, Karl Franzens University
(Graz, Austria) for trace element analysis [48]. The la-
boratory uses calibration blanks and calibration stan-
dards, calibration checks, sample spikes and blanks, NIES
No 18 Human urine, and in-house urine reference sam-
ples for quality control/quality assurance purposes. Con-
centrations of iAs, MMA, and DMA were determined by
anion-exchange high performance liquid chromatography
(HPLC; Agilent 1100, Agilent Technologies, Waldbronn,
Germany) coupled to inductively coupled plasma mass
spectrometry (ICPMS) (Agilent 7700x). The limits of de-
tection were 0.1 μg/L for iAs, MMA, and DMA. The
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DMA for the in-house reference urine specimens were
6.0%, 6.5%, and 5.9%.
Statistical analysis methods
To evaluate arsenic metabolism, we calculated %iAs,
%MMA, and %DMA as the relative contribution of iAs,
MMA, or DMA to their sum, multiplied by 100, and
analyzed the association of each % species biomarker
with each measure of body composition (body mass
index, percent body fat, fat free mass and waist circum-
ference) separately using linear regression models. Body
mass index was categorized as < 25, ≥25 and < 30, ≥30
and < 35 and ≥35 kg/m2. Percent body fat, fat free mass
and waist circumference were categorized as sex-specific
quartiles. Adjusted models accounted for study region, age
(< 55 and ≥55 years), sex, smoking status (current/ever/
never), drinking status (current/ever/never), high school
completion (yes/no), and quartiles of total urine arsenic
adjusted for specific gravity. To obtain quartiles of total
urine arsenic adjusted for specific gravity (a proxy for urine
dilution of the spot urine sample), we fit linear regressions
of measured urine arsenic on specific gravity and took
quartiles of the residuals. We considered sensitivity ana-
lyses adjusting for restricted cubic splines of continuous
variables (e.g. age, specific gravity-corrected arsenic) with
consistent findings (data not shown). In addition to evalu-
ating each measure of body composition separately, we
also contrasted the four measures of body composition in
models with multiple measures of body composition. Be-
cause both arsenic metabolism and adiposity differ by sex,
we evaluated the association between % arsenic species
and measures of body composition stratified by sex, with
consistent findings (data not shown). Because approxi-
mately half of the study population had diabetes [49], we
also evaluated the association between % arsenic species
and adiposity by diabetes status with consistent findings
(data not shown).
The %iAs, %MMA and %DMA are skewed distribu-
tions but not log-normal (Additional file 2: Appendix 2),
resulting in a poor fit for linear regression models. In a
sensitivity analysis, we used generalized gamma regres-
sion [50] to evaluate the association between urine ar-
senic metabolism biomarkers with measures of body
composition. The generalized gamma distribution is
characterized by a location parameter β that defines the
position of the distribution median, a scale parameter σ
that reflects the distribution’s spread, and a shape param-
eter κ that defines the family of the distribution (lognor-
mal, gamma, Weibull, etc.). We also conducted a second
sensitivity analysis using beta regression for each % arsenic
species (divided by 100) since these biomarkers are
proportion data [51] and Dirichlet regression, a multi-
variate modification of the beta regression that modelsall % arsenic species as a set that must sum to one
[52]. All statistical analyses were performed in Stata/
SE 11.2, augmented with < dirifit > and < betafit > contrib-
uted packages.
Results
Mean (SD) body mass index, percent body fat, fat free
mass and waist circumference were 30.9 (6.3) kg/m2,
36.2 (9.1)%, 53 (11)%, and 105.4 (14.7) cm, respectively.
The Spearman correlation coefficient was 0.66 between
body mass index and percent body fat, 0.36 between
body mass index and fat free mass, 0.88 between body
mass index and waist circumference, -0.35 between per-
cent body fat and fat free mass, and 0.63 between per-
cent body fat and waist circumference (Table 1).
Median (IQR) were 7.9 (5.6, 11.0)% for %iAs, 13.9
(10.8, 17.5)% for MMA and 77.8 (72.0, 82.7)% for %DMA
(Table 2). The %iAs and %MMA biomarkers were mod-
erately positively correlated (Spearman correlation coeffi-
cient 0.47), while %DMA was strongly negatively
correlated with %iAs and %MMA (Spearman correlation
coefficients −0.82 and −0.87, respectively) (Table 1).
Median %iAs was higher in men, younger participants,
current smokers, and current drinkers, and lower in
Oklahoma (Table 2). Median %MMA was higher in men,
older participants, participants from North and South
Dakota, and current smokers. Median %DMA was lower
in men, participants from North and South Dakota,
current smokers and current drinkers.
In crude analyses, %iAs and %MMA were inversely re-
lated to body mass index (Spearman correlations −0.16,
-0.32, respectively), percent body fat (−0.25, -0.35), and
waist circumference (−0.15, -0.29), and positively related
to fat free mass (0.15, 0.07) (Table 1). %DMA was posi-
tively related to body mass index (0.28), % body fat (0.35)
and waist circumference (0.27), and inversely related to fat
free mass (−0.12) (Table 1). All these Spearman correla-
tions were significant at p < 0.0001. The correlations be-
tween fat free mass and %iAs, %MMA and %DMA were
confounded by sex, and in analyses using sex-specific
quartiles of fat free mass the crude associations were in
the same direction as for the other measures of body com-
position (Table 3, Table 4).
Increasing body mass index categories remained asso-
ciated with lower mean %iAs (−1.7, comparing BMI ≥ 35
to BMI < 25, with 95% CI: -2.2, -1.2) and %MMA (−4.0,
95% CI: -4.5, -3.5) and higher mean %DMA (+5.7,
95% CI: 4.8, 6.5) after adjustment for arsenic exposure
and demographics (Table 3). Similar dose responses were
observed for % body fat, fat free mass, and waist circum-
ference when analyzed in separate models. In models
adjusting for other measures of body composition at the
same time, higher body mass index remained associated
with lower %iAs and %MMA and higher %DMA. For
Table 1 Spearman correlation coefficients of body composition measures and arsenic metabolism biomarkers
Body mass index % Body fat Fat free body mass Waist circumference % iAs % MMA % DMA
Body mass index 1.00
% Body fat 0.66 1.00
Fat free body mass 0.36 −0.35 1.00
Waist circumference 0.88 0.63 0.33 1.00
% iAs - 0.16 −0.25 0.15 −0.16 1.00
% MMA - 0.32 −0.35 0.07 −0.29 0.47 1.00
% DMA 0.29 0.35 −0.12 0.27 −0.82 −0.87 1.00
N = 3,663 participants.
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cies disappeared when adjusted for body mass index but
remained when adjusting for % body fat and fat free
mass. For % body fat and fat free mass, the associations
disappeared when adjusting for body mass index orTable 2 Arsenic metabolite proportions by participant charac
Participants N (%) % iAs median (IQR) P value
Overall 3,663 7.9 (5.6, 11.0)
Sex
Female 2,157 (58. 9) 7.0 (5.0, 10.0)
Male 1,506 (41.1) 9.4 (6.7, 12.9) <0.001
Age
< 55 years 1,836 (50.1) 8.5 (6.0, 11.5)
≥ 55 and < 65 years 1,190 (32.5) 7.6 (5.4, 10.5)
≥ 65 years 637 (17.4) 7.1 (5.0, 9.7) <0.001
BMI
< 25 kg/m2 557 (15.2) 9.1 (6.2, 12.4)
≥25 and < 30 kg/m2 1,236 (33.7) 8.4 (5.8, 11.5)
≥30 and < 35 kg/m2 1,057 (28.9) 7.5 (5.5, 10.5)
≥35 kg/m2 813 (22.2) 7.1 (5.2, 9.8) <0.001
Study center
Arizona 1,281 (35.0) 8.6 (6.1, 11.5)
Oklahoma 1,141 (31.2) 6.6 (4.6, 9.3)
North or South Dakota 1,241 (33.9) 8.4 (6.1, 11.7) <0.001
Smoking status
Never 1,177 (32.1) 7.4 (5.3, 10.1)
Former 1,240 (33.9) 7.6 (5.4, 10.5)
Current 1,246 (34.0) 9.0 (6.1, 12.2) <0.001
Drinking status
Never 575 (15.7) 7.1 (5.2, 9.8)
Former 1,517 (41.4) 7.6 (5.4, 10.8)
Current 1,571 (42.9) 8.4 (5.9, 11.7) <0.001
High school completion
Yes 1,793 (47.5) 7.7 (5.5, 10.8)
No 1,924 (52.5) 8.3 (5.7, 11.2) 0.002
*P values are from Kruskal-Wallis tests.
Arsenic % species must sum to 100% within each person.waist circumference, and were attenuated when adjust-
ing for each other.
Our sensitivity analyses using generalized gamma re-
gression, beta regression and Dirichlet regression were
consistent with the findings obtained by linear regressionteristics
% MMA median (IQR) P value % DMA median (IQR) P value
13.9 (10.8, 17.5) 77.8 (72.0, 82.7)
13.0 (10.0, 16.0) 79.7 (74.7, 84.1)
15.7 (12.4, 19.4) <0.001 74.5 (67.9, 80.0) <0.001
13.9 (10.8, 17.6) 77.3 (71.7, 82.2)
13.6 (10.7, 17.3) 78.6 (72.4, 83.3)
14.6 (11.2, 17.8) 0.03 78.2 (72.4, 82.7) 0.005
16.7 (13.2, 20.3) 74.4 (67.3, 79.6)
15.0 (11.6, 18.5) 76.3 (70.5, 81.3)
13.3 (10.5, 16.5) 78.9 (73.3, 83.3)
11.9 (9.1, 14.8) <0.001 80.8 (75.9, 85.3) <0.001
13.3 (10.4, 16.4) 78.1 (72.6, 82.5)
13.4 (10.2, 16.7) 79.6 (74.0, 84.3)
15.3 (11.9, 19.2) <0.001 75.9 (69.6, 81.1) <0.001
13.3 (10.1, 16.3) 79.0 (73.9, 83.5)
13.6 (10.8, 17.1) 78.4 (72.8, 83.2)
15.2 (11.6, 19.0) <0.001 75.8 (69.2, 81.3) <0.001
13.5 (10.6, 16.6) 79.2 (73.6, 83.3)
13.9 (10.8, 17.3) 78.1 (72.4, 83.0)
14.2 (10.8, 18.0) 0.008 77.0 (70.8, 82.2) <0.001
13.9 (10.7, 17.3) 78.0 (72.3, 83.0)
13.9 (10.8, 17.7) 0.28 77.6 (71.7, 82.5) 0.03
Table 3 Difference (95% CI) of mean % arsenic species in urine by body composition measure categories
% iAs % MMA % DMA
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Body mass index
< 25 kg/m2 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent)
≥ 25, < 30 kg/m2 −0.8 (−1.3, -0.3) −0.7 (−1.2, -0.3) −1.5 (−2.0, -1.0) −1.4 (−1.9, -1.0) 2.3 (1.5, 3.2) 2.2 (1.4, 3.0)
≥ 30, < 35 kg/m2 −1.8 (−2.3, -1.3) −1.6 (−2.0, -1.1) −3.1 (−3.6, -2.6) −2.8 (−3.3, -2.3) 4.9 (4.0, 5.7) 4.3 (3.5, 5.1)
≥ 35 −2.3 (−2.8, -1.7) −1.7 (−2.2, -1.2) −4.8 (−5.4, -4.3) −4.0 (−4.5, -3.5) 7.1 (6.2, 8.0) 5.7 (4.8, 6.5)
P for trend < 0.001 <0.001 <0.001 <0.001 <0.001 <0.001
% Body fat
Quartile 1 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent)
Quartile 2 −0.6 (−1.1, -0.2) −0.6 (−1.0, -0.2) −1.2 (−1.7, -0.8) −1.1 (−1.6, -0.7) 1.9 (1.1, 2.7) 1.7 (1.0, 2.4)
Quartile 3 −0.9 (−1.4, -0.5) −0.8 (−1.2, -0.4) −1.9 (−2.4, -1.4) −1. 7 (−2.1, -1.2) 2.8 (2.1, 3.6) 2.5 (1.8, 3.2)
Quartile 4 −1.2 (−1.6, -0.7) −1.2 (−1.6, -0.7) −3.0 (−3.4, -2.5) −2.6 (−3.1, -2.2) 4.1 (3.4, 4.9) 3.8 (3.1, 4.5)
P for trend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Fat free mass
Quartile 1 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent)
Quartile 2 −0.8 (−1.2, -0.3) −0.8 (−1.2, -0.4) −1.2 (−1.7, -0.7) −1.2 (−1.7, -0.8) 2.0 (1.2, 2.7) 2.0 (1.3, 2.7)
Quartile 3 −0.6 (−1.1, -0.2) −0.7 (−1.1, -0.2) −1.5 (−2.0, -1.1) −1.6 (−2.0, -1.1) 2.2 (1.4, 2.9) 2.2 (1.5, 2.9)
Quartile 4 −1.5 (−1.9, -1.0) −1.4 (−1.9, -1.0) −2.9 (−3.4, -2.5) −2.8 (−3.3, -2.3) 4.4 (3.6, 5.2) 4.2 (3.5, 5.0)
P for trend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Waist circumference
Quartile 1 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent) 0.0 (referent)
Quartile 2 −0.8 (−1.2, -0.3) −0.8 (−1.2, -0.4) −1.2 (−1.7, -0.7) −1.2 (−1.7, -0.8) 2.0 (1.2, 2.8) 2.0 (1.3, 2.7)
Quartile 3 −1.2 (−1.7, -0.8) −1.2 (−1.6, -0.8) −2.3 (−2.7, -1.8) −2.2 (−2.6, -1.7) 3.5 (2.7, 4.2) 3.3 (2.6, 4.1)
Quartile 4 −1.6 (−2.0, -1.2) −1.6 (−2.1, -1.2) −3.4 (−3.9, -3.0) −3.2 (−3.6, -2.7) 5.0 (4.3, 5.8) 4.8 (4.1, 5.5)
P for trend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Adjusted linear regression models control for age, sex, specific gravity-corrected arsenic, education, and drinking and smoking status.
Quartiles for waist circumference, % body fat and fat free mass use sex-specific cutpoints.
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gamma and beta regression models allowed us to evaluate
differences in % arsenic species variability with increasing
body mass index, showing that variability decreased with
increasing body mass index categories (Figure 1). The shift
of the population to more %DMA and less heterogeneity
across individuals with increasing body mass index was
also apparent from the multivariate Dirichlet analysis of
all % arsenic species biomarkers (Figure 2). Results for
each biomarker’s relationship with body mass index were
similar in univariate beta regression and multivariate
Dirichlet regression (Additional file 3: Appendix 3).
Conclusion
Body mass index, % body fat, fat free mass and waist
circumference were associated with lower %iAs, lower
%MMA, and higher %DMA in urine of the Strong Heart
Study participants. The associations remained similar after
adjustment for age, sex, study center, education, drinking
status, smoking status and urine arsenic levels. In analysesthat adjusted for other measures of body composition,
body mass index remained associated with % arsenic spe-
cies while waist circumference remained associated when
adjusted for % body fat or fat free mass but not when ad-
justed for body mass index. These findings indicate that
body size is associated with % arsenic species, with higher
body size being related to higher % DMA in urine. It is
unclear, however, if the associations observed are due to
adiposity, fat free mass, body size, or some other con-
struct. Information bias from measurement error and cor-
relation across body composition variables could explain
the findings of models that adjust for multiple body com-
position variables. At first glance, the results of Table 4
might be interpreted as an indication that body size, as
measured by body mass index, rather than adiposity or fat
free mass, is what drives the association with arsenic me-
tabolism. However, body mass index is likely the most pre-
cisely measured measure of body composition of those
evaluated in this study, followed by waist circumference
[53], which in turn is likely more precise than the two
Table 4 Difference (95% CI) of % arsenic species in urine by one unit increase in body composition measure categories in unadjusted models and in models
adjusted for other measures of body composition
% MMA by % DMA by
BMI % body fat fat free mass WC BMI % body fat fat free mass WC
Unadjusted models
Measure −1.6 (−1.8, -1.4) −1.0 (−1.1, -0.8) −0.9 (−1.1, -0.8) −1.1 (−1.3, -1.0) 2.4 (2.1, 2.6) 1.3 (1.1, 1.6) 1.3 (1.1, 1.6) 1.7 (1.4, 1.9)
Models with multiple body composition measures
BMI, % body fat −1.8 (−2.0, -1.5) 0.2 (0.0, 0.4) - - 2.7 (2.4, 3.1) −0.4 (−0.8, -0.1) - -
BMI, fat free −1.7 (−1.9, -1.5) - 0.1 (−0.1, 0.3) - 2.5 (2.1, 2.9) - −0.2 (−0.5, 0.2) -
BMI, WC −1.7 (−1.9, -1.4) - - 0.1 (−0.2, 0.3) 2.5 (2.1, 3.0) - - −0.2 (−0.6, 0.2)
% Fat, fat free - −0.7 (−0.9, -0.6) −0.7 (−0.8, -0.5) - - 1.0 (0.7, 1.2) 1.0 (0.7, 1.2) -
% Fat, WC - −0.3 (−0.5, -0.1) - −0.9 (−1.1, -0.7) - 0.4 (0.0, 0.7) - 1.4 (1.1, 1.7)
BMI, % fat, fat free −1.9 (−2.2, -1.6) 0.2 (0.0, 0.5) 0.1 (−0.1, 0.4) - 3.0 (2.5, 3.5) −0.5 (−0.9, -0.2) −0.3 (−0.6, 0.0) -
BMI, % fat, WC −1.8 (−2.1, -1.5) 0.2 (0.0, 0.4) - 0.0 (−0.3, 0.3) 2.8 (2.3, 3.2) −0.4 (−0.8, -0.1) - 0.0 (−0.4, 0.4)
% fat, fat free, WC - −0.4 (−0.6, -0.2) −0.4 (−0.6, -0.2) −0.6 (−0.9, -0.4) - 0.5 (0.1, 0.8) 0.6 (0.2, 0.9) 1.0 (0.6, 1.4)
All −1.9 (−2.2, -1.5) 0.3 (0.0, 0.5) 0.2 (−0.1, 0.4) −0.1 (−0.3, 0.2) 3.0 (2.4, 3.5) −0.6 (−1.0, -0.2) −0.3 (−0.7, 0.0) 0.1 (−0.3, 0.6)
BMI: body mass index; WC: waist circumference.
















Figure 1 Maximum likelihood estimates of generalized gamma models for % arsenic species by body composition measures. The
upper panel shows the crude associations of each % species with body mass index categories. The lower panel shows the residual association
adjusting for categories of other body composition measures. Models allowed flexibility in location (β) and scale (σ). The % arsenic species are
labeled at the marginal medians for each arsenic species.
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free mass [54]. In multivariable models, it is possible to
transfer the association from a casual exposure to a better
measured co-exposure that is not necessarily causally re-
lated to the outcome when there are positive correlation
in exposures’ true values but negative correlations in
measurement errors [55]. Thus, it is plausible that the
consistently strong associations found with body mass
index may be due to body mass index acting as a “sponge”
for associations with other variables. To further disentan-
gle the association of body composition measures with ar-
senic metabolism, it would be helpful to have multiple
measures from the same visit of body mass index, % body
fat, fat free mass and waist circumference to obtain esti-
mates of the test-retest reliability of each measure in this
population and more explicitly model the measurement
error dependence.Figure 2 Multivariate associations of body mass index and % arsenic
(% iAs, % MMA and % DMA) lie on a simplex. As body mass increases, ove
are less heterogeneous across individuals within the same body mass indeDespite the challenges posed by measurement error
for understanding the etiologic basis for the association,
body mass index was cross-sectionally associated with
the pattern of arsenic metabolites in urine. This associ-
ation might be related to adiposity. Previous studies have
shown that %DMA increases as women progress through
pregnancy [56,57]. While the shifts are similar to those ob-
served with increased body size in our study, it is unknown
if those changes in arsenic metabolism during pregnancy
are related to the concomitant gain in maternal body fat
and body size [58,59]. Arsenic has been related to adiposity
and to adipocyte differentiation in experimental models
[60-63], although to our knowledge the roles of arsenic
metabolism processes have not been evaluated. The associ-
ation between body mass index and % arsenic metabolites
may also be related to muscle mass. Creatinine, a break-
down product of creatine phosphate in muscle is generallyspecies in urine using Dirichlet regression. The % arsenic species
rall metabolism shifts to greater % DMA, and the metabolism profiles
x stratum.
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http://www.ehjournal.net/content/12/1/107produced at a constant rate depending on muscle mass
[64]. Creatinine may be a surrogate for several key media-
tors of the arsenic metabolism process as both arsenic me-
tabolism [65] and creatine synthesis [66] use S-adenosyl
methionine (SAM) as the methyl-donor. During methyla-
tion, SAM generates homocysteine which needs to be
remethylated using folate and vitamin B12 [67] in order to
be used again for methylation. Alternatively, homocysteine
may form glutathione which is also important for arsenic
species reduction and cellular efflux [67,68]. Experimental
models are needed to evaluate if the connection between
arsenic metabolism and measures of body composition are
related to adiposity or to muscle mass.
We also found that those with higher body mass index
had less variability in their distribution of %DMA than
those with lower body mass index. To our knowledge
this has never been explicitly discussed in previous stud-
ies. However, this same pattern is visible in published
histograms of %DMA compared over the development
of pregnancy [56,57]. It has been shown that as women
progress through pregnancy, they have higher %DMA in
urine and more peaked distributions of %DMA [56,57],
much like the patterns seen across body size groups in
our study. We suspect that the reduced variability with in-
creasing adiposity or with the progression of pregnancy
may reflect a constraint on maximum possible %DMA. It
would be interesting to evaluate if the pattern observed
during pregnancy is related to increased adiposity.
Our study has a number of strengths and limitations.
Strengths include the large sample size, multiple measures
of body size, and the laboratory techniques for arsenic spe-
ciation, characterized by low limits of detection. Similar to
other studies on arsenic metabolism, we are limited by the
absence of data on arsenic species intake and routes of ex-
posure. However, it is likely that the primary arsenic expos-
ure for our population is inorganic arsenic from drinking
water and that MMA and DMA observed in urine are
mainly from metabolized inorganic arsenic [49]. The lack
of data on arsenic species concentrations within the body,
for instance in blood or adipose tissue, also limits pharma-
cokinetic inferences. This is a cross-sectional study, and
the direction of the association is uncertain. Study designs
with longitudinal data might enable evaluating the direc-
tion of the association and the impact of changes in body
mass index in arsenic metabolism. Genetic advances char-
acterizing arsenic metabolism could potentially enable
Mendelian randomization studies of arsenic metabolism
and adiposity [69]. Unmeasured confounding is possible.
However, since these are large-magnitude associations, the
unmeasured variables would need to be highly aliased with
body size and with arsenic metabolite proportions to ex-
plain the observed associations. Fat-soluble chemicals for
instance are strongly related to adiposity, but their relation-
ship to arsenic metabolism is unknown.Conclusions
Body mass index was associated with arsenic metabolite
distributions in urine even after adjustment for other
measures of body composition. These findings suggest
that increased body size is related to higher % DMA in
urine, although we could not reach firm conclusions
whether the association with body mass index is related
to adiposity or fat free body mass, due to the potential
impact of measurement error in models with multiple
measures of body composition. Potentially, the associ-
ation with body mass index could also be related to body
size per se, rather than only adiposity or fat free mass.
Experimental research can potentially advance our un-
derstanding of the relationship between body compos-
ition and arsenic metabolism. Prospective epidemiologic
studies are also needed to evaluate the direction of the
relationship between arsenic metabolism and body mass
index. Inter-individual differences in arsenic metabolism
may be important for population-level variation in arsenic
susceptibility. Given the association between body mass
index and arsenic metabolism, epidemiologic studies of
arsenic health effects should examine whether body mass
index may be a modifier of arsenic disease risks.
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